Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Non-Congress | TCXpress™, a novel promising TCR platform

David Apelian • 29 Apr 2022
Non-Congress
General

David Apelian, MD, PhD, BlueSphere Bio, Pittsburgh, PA, highlights the key features and advantages of TCXpress™, a novel T-cell receptor (TCR) platform. TCXpress™ is able to capture, express, and characterize thousands of TCRs targeted to any antigen expressed inside or on the surface of a cancer cell in a very short time. This technology will be used as a platform for discovery and partnering. This interview was recorded virtually.

More from David Apelian

3:17
TCXpress™ vs CAR-T therapy & targeting leukemia with TCR T-cells
David Apelian • 29 Apr 2022
2:49
Identifying novel antigens for TCR T-cell therapy
David Apelian • 29 Apr 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals